Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report
- PMID: 36056113
- PMCID: PMC9440143
- DOI: 10.1038/s41598-022-18875-5
Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report
Abstract
Quantification of the relative ellipsoid zone reflectivity (rEZR) might be a structural surrogate parameter for an early disease progression in the context of age-related macular degeneration (AMD). Within the European multicenter, cross-sectional MACUSTAR study, we have devised an automatic approach to determine the mean rEZR [arbitrary units, AU] at two independent visits in SD-OCT volume scans in study participants. Linear mixed-effects models were applied to analyze the association of AMD stage and AMD associated high-risk features including presence of pigmentary abnormalities, reticular pseudodrusen (RPD), volume of the retinal-pigment-epithelial-drusenoid-complex (RPEDC) with the rEZR. Intra-class correlation coefficients (ICC) were determined for rEZR reliability analysis. Within the overall study cohort (301 participants), we could observe decreased rEZR values (coefficient estimate ± standard error) of - 8.05 ± 2.44 AU (p = 0.0011) in the intermediate and of - 22.35 ± 3.28 AU (p < 0.0001) in the late AMD group. RPD presence was significantly associated with the rEZR in iAMD eyes (- 6.49 ± 3.14 AU; p = 0.0403), while there was a good ICC of 0.846 (95% confidence interval: 0.809; 0.876) in the overall study cohort. This study showed an association of rEZR with increasing disease severity and the presence of iAMD high-risk features. Further studies are necessary to evaluate the rEZR's value as a novel biomarker for AMD and disease progression.
© 2022. The Author(s).
Conflict of interest statement
M.S.: Heidelberg Engineering: non-financial support; Optos: non-financial support, Zeiss: non-financial support, CenterVue: non-financial support. C.B.: No financial disclosures. B.I.: No financial disclosures. M.Sc.: No financial disclosures. R.F.: Alimera: personal fees, Apellis: personal fees, Bayer: personal fees, non-financial support, Boehringer-Ingelheim: personal fees, Biogen: non-financial support, CenterVue: non-financial support, Chiesi: personal fees, Roche/Genentech: personal fees, non-financial support, Novartis: personal fees, non-financial support, ProQR: personal fees, Oxford Innovation: personal fees, Santhera: personal fees. F.H.: Acucela: personal fees, non-financial support, Allergan: non-financial support, Apellis: personal fees, non-financial support, Bayer: personal fees, non-financial support, Boehringer-Ingelheim: personal fees, Bioeq/Formycon: non-financial support, personal fees, CenterVue: non-financial support, Ellex: non-financial support, Roche/Genentech: personal fees, non-financial support, Geuder: personal fees, non-financial support, Graybug: personal fees, Gyroscope: personal fees, Heidelberg Engineering: personal fees, non-financial support, IvericBio: personal fees, non-financial support, Kanghong: personal fees, non-financial support, LinBioscience: personal fees, NightStarX: non-financial support, Novartis: personal fees, non-financial support, Optos: non-financial support, Oxurion: personal fees, Pixium Vision: personal fees, non-financial support, Oxurion: personal fees, Stealth BioTherapeutics: personal fees, Zeiss: non-financial support, personal fees, STZ GRADE Reading Center: Owner. S.S.V.: AlphaRET: personal fees, Apellis: personal fees, Bayer: non-financial support, Bioeq: personal fees, Carl Zeiss MediTec: non-financial support, Heidelberg Engineering: non-financial support, personal fees, Katairo: personal fees, Kubota Vision: personal fees, Novartis: personal fees, non-financial support, Oxurion: personal fees, Pixium: personal fees, Roche: personal fees, non-financial support, SparingVision: personal fees, STZ GRADE Reading Center: Owner. M.P.: Appelis: personal fees. S.T.: Heidelberg Engineering: personal fees, non-financial support; Optos: non-financial support, Zeiss: non-financial support, CenterVue: non-financial support; Novartis: personal fees; Bayer: personal fees; Allergan: personal fees.
Figures




References
-
- Allingham, M., Mettu, P. & Cousins, S. Elamipretide, a mitochondrial-targeted drug, for the treatment of vision loss in dry AMD with high risk drusen: Results of the Phase 1 ReCLAIM study. Investig. Ophthalmol. Vis. Sci., 974 (2018).
-
- ReCLAIM-2 study to evaluate safety, efficacy and pharmacokinetics of elamipretide in subjects with AMD with non-central GA. https://clinicaltrials.gov/ct2/show/NCT03891875. Accessed July 20, 2021.